Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18988307 | HUMANIZED ANTIBODIES AGAINST IRHOM2 | December 2024 | March 2025 | Allow | 3 | 0 | 0 | Yes | No |
| 18962263 | ANTI-S100A4 HUMANIZED ANTIBODIES, USES AND METHODS | November 2024 | April 2025 | Allow | 4 | 1 | 1 | No | No |
| 18895539 | HEPARANASE-NEUTRALIZING A54 MONOCLONAL ANTIBODY | September 2024 | June 2025 | Allow | 8 | 1 | 0 | Yes | No |
| 18597624 | REGIMENS AND METHODS OF TREATING MULTIPLE SCLEROSIS USING OFATUMUMAB | March 2024 | February 2025 | Allow | 11 | 1 | 1 | Yes | No |
| 18515714 | ANTIBODIES THAT BIND TO C1S AND USES THEREOF | November 2023 | April 2024 | Allow | 5 | 0 | 1 | Yes | No |
| 18486137 | ANTIBODIES TO 25-HYDROXYVITAMIN D2 AND D3 FOR DETECTING TOTAL 25-HYDROXYVITAMIN D | October 2023 | May 2025 | Allow | 19 | 1 | 0 | No | No |
| 18481529 | COMPOSITIONS AND METHODS FOR TREATMENT OF CHRONIC LUNG DISEASES | October 2023 | August 2024 | Allow | 10 | 2 | 1 | Yes | No |
| 18356928 | Anti-Dectin-2 Antibodies and Methods of Using | July 2023 | February 2025 | Allow | 19 | 0 | 0 | No | No |
| 18329172 | ANTI-TMPRSS6 ANTIBODIES AND USES THEREOF | June 2023 | September 2023 | Allow | 3 | 0 | 0 | Yes | No |
| 18312339 | ANTIGEN BINDING RECEPTORS SPECIFIC FOR MUTATED Fc DOMAINS | May 2023 | December 2024 | Allow | 20 | 0 | 0 | No | No |
| 18302645 | POLYPEPTIDE USEFUL IN ADOPTIVE CELL THERAPY | April 2023 | November 2024 | Abandon | 19 | 0 | 0 | No | No |
| 18300307 | METHOD OF TREATING RHEUMATOID ARTHRITIS USING ANTIBODIES TO OXIDIZED PHOSPHOLIPIDS | April 2023 | September 2024 | Allow | 18 | 0 | 0 | No | No |
| 18187928 | Antibody Immune Cell Inhibitor Fusion Proteins | March 2023 | June 2025 | Abandon | 27 | 0 | 1 | No | No |
| 18122948 | ANTIBODY BINDING TO A LINKER PEPTIDE | March 2023 | June 2024 | Allow | 15 | 0 | 0 | No | No |
| 18172059 | COMPOSITIONS AND METHODS FOR CAPTURING EXOSOMES | February 2023 | December 2024 | Allow | 22 | 1 | 0 | Yes | No |
| 18159728 | METHODS OF DETERMINING THE FUNCTION OF POLYUBIQUITIN USING ANTI-POLYUBIQUITIN ANTIBODIES | January 2023 | September 2024 | Allow | 20 | 0 | 0 | Yes | No |
| 18055992 | METHODS FOR MODULATING INTESTINE CELLS OR TISSUE FUNCTION | November 2022 | April 2025 | Abandon | 29 | 3 | 1 | Yes | No |
| 18054080 | COMPOSITIONS AND METHODS FOR ENHANCING DONOR OLIGONUCLEOTIDE-BASED GENE EDITING | November 2022 | November 2024 | Abandon | 24 | 2 | 1 | No | No |
| 17976613 | COMPOSITIONS FOR IMPROVING KIDNEY FUNCTION IN PATIENTS WITH HEPATORENAL SYNDROME | October 2022 | May 2025 | Abandon | 30 | 4 | 0 | Yes | Yes |
| 17996601 | ANTIBODY CAPABLE OF BINDING SPECIFICALLY TO 5' TO 3' EXONUCLEASE ACTIVE DOMAIN OF DNA POLYMERASE | October 2022 | December 2023 | Allow | 14 | 1 | 1 | Yes | No |
| 18045313 | COMPOSITIONS AND METHODS OF TREATING LUPUS NEPHRITIS | October 2022 | February 2025 | Abandon | 28 | 0 | 1 | No | No |
| 17916008 | ANTI-TMPRSS6 ANTIBODIES AND USES THEREOF | September 2022 | September 2024 | Allow | 24 | 0 | 1 | Yes | No |
| 17887952 | ANTI-CERAMIDE ANTIBODIES | August 2022 | September 2024 | Abandon | 25 | 1 | 0 | No | No |
| 17854808 | METHODS AND USES FOR PROPROTEIN CONVERTASE SUBTILISIN KEXIN 9 (PCSK9) INHIBITORS | June 2022 | December 2024 | Abandon | 29 | 1 | 0 | No | No |
| 17836862 | ANTIGEN BINDING MOLECULES SPECIFIC FOR AN ANTI-CD19 SCFV | June 2022 | September 2024 | Allow | 27 | 1 | 1 | No | No |
| 17743177 | ANTIBODIES SPECIFIC FOR HUMAN ALPHA-SYNUCLEIN FOR TREATING ALPHA-SYNUCLEINOPATHIES | May 2022 | March 2025 | Allow | 34 | 1 | 1 | Yes | No |
| 17660317 | DOSE | April 2022 | January 2025 | Abandon | 33 | 3 | 1 | No | Yes |
| 17666252 | METHODS OF TREATING SKIN DISORDERS | February 2022 | September 2024 | Abandon | 32 | 2 | 1 | No | No |
| 17578014 | CD38 ANTIBODY | January 2022 | April 2024 | Allow | 27 | 1 | 0 | No | No |
| 17537786 | METHODS FOR TREATING GI SYNDROME AND GRAFT VERSUS HOST DISEASE | November 2021 | June 2024 | Allow | 31 | 1 | 0 | No | No |
| 17531011 | ANTI-CD20 ANTIBODY | November 2021 | March 2024 | Allow | 28 | 1 | 1 | Yes | No |
| 17519063 | DOSING REGIMEN OF COMBINATION OF ANTI-CD20 AND ANTI-BLYS ANTIBODIES | November 2021 | April 2024 | Allow | 29 | 2 | 0 | No | No |
| 17515001 | Modulation of Proprotein Convertase Subtilisin/Kexin 9 Expression (PCSK9) with HSP 27 and/or HSP25 | October 2021 | March 2024 | Allow | 29 | 2 | 0 | No | No |
| 17504921 | METHODS FOR REDUCING CARDIOVASCULAR RISK | October 2021 | September 2024 | Abandon | 35 | 1 | 1 | No | No |
| 17495559 | REGIMENS AND METHODS OF TREATING MULTIPLE SCLEROSIS USING OFATUMUMAB | October 2021 | February 2024 | Abandon | 28 | 1 | 0 | No | No |
| 17493896 | PHARMACEUTICAL COMPOSITIONS AND METHODS TARGETING WNT PATHWAY PROTEINS | October 2021 | December 2023 | Allow | 27 | 1 | 0 | No | No |
| 17484794 | METHOD OF DETECTING TIM-3 USING ANTIBODY MOLECULES TO TIM-3 | September 2021 | June 2024 | Abandon | 33 | 1 | 1 | No | No |
| 17460883 | ANTI-PSGL-1 ANTIBODIES AND USES THEREOF | August 2021 | December 2023 | Allow | 27 | 2 | 0 | No | No |
| 17370446 | METHODS OF TREATING ANAEMIA | July 2021 | December 2023 | Abandon | 29 | 1 | 0 | No | No |
| 17293134 | POLYPEPTIDE CONJUGATES | May 2021 | November 2024 | Abandon | 43 | 0 | 1 | No | No |
| 17241628 | ANTIBODIES SPECIFICALLY BINDING TO MASP-3 FOR THE TREATMENT OF VARIOUS DISEASES AND DISORDERS | April 2021 | September 2023 | Allow | 29 | 1 | 1 | No | No |
| 17221515 | ALIMENTARY AND SYSTEMIC ANTIVIRAL THERAPEUTICS | April 2021 | October 2023 | Abandon | 31 | 0 | 1 | No | No |
| 17211619 | ANTI-CD20 GLYCOANTIBODIES AND USES THEREOF | March 2021 | September 2023 | Allow | 30 | 4 | 1 | Yes | Yes |
| 17203671 | METHOD FOR TREATING MULTIPLE SCLEROSIS | March 2021 | March 2024 | Abandon | 36 | 1 | 1 | No | No |
| 17270827 | SUICIDE MODULE COMPOSITIONS AND METHODS | February 2021 | August 2024 | Allow | 42 | 1 | 1 | No | No |
| 17127202 | MEDICAMENT COMPRISING ANTI-PHOSPHOLIPASE D4 ANTIBODY | December 2020 | November 2023 | Abandon | 35 | 1 | 1 | No | No |
| 17253824 | METHOD FOR SEPARATING ANTIBODY, AND METHOD FOR TESTING ON DISEASE | December 2020 | May 2025 | Allow | 53 | 2 | 1 | Yes | No |
| 17101780 | Reducing Immune Tolerance Induced by PD-L1 | November 2020 | November 2023 | Allow | 35 | 1 | 1 | Yes | No |
| 17091375 | ANTIBODIES TO CD40 | November 2020 | October 2024 | Abandon | 47 | 3 | 1 | Yes | No |
| 17087914 | ANTIBODIES TO 25-HYDROXYVITAMIN D2 AND D3 | November 2020 | May 2023 | Allow | 30 | 1 | 0 | Yes | No |
| 17030627 | ANTI-CXCL13 ANTIBODIES AND METHODS OF USING THE SAME | September 2020 | January 2024 | Allow | 40 | 1 | 1 | No | No |
| 17015212 | DKK1 ANTIBODIES AND METHODS OF USE | September 2020 | June 2023 | Abandon | 33 | 2 | 1 | No | No |
| 17010354 | PLASMA KALLIKREIN BINDING PROTEINS AND USES THEREOF IN TREATING HEREDITARY ANGIOEDEMA | September 2020 | April 2025 | Allow | 55 | 3 | 1 | No | No |
| 16991269 | METHODS FOR REDUCING OR ELIMINATING THE NEED FOR LIPOPROTEIN APHERESIS IN PATIENTS WITH HYPERLIPIDEMIA BY ADMINISTERING ALIROCUMAB | August 2020 | October 2023 | Allow | 38 | 1 | 1 | No | No |
| 16966513 | NUCLEIC ACID MONOCLONAL ANTIBODIES TARGETING PCSK9 AND METHODS OF USE | July 2020 | May 2024 | Allow | 46 | 3 | 1 | No | No |
| 16958945 | Methods for Measuring Renalase | June 2020 | October 2024 | Allow | 51 | 2 | 1 | Yes | No |
| 16911954 | ANTI-COMPLEMENT FACTOR C1Q FAB FRAGMENTS AND USES THEREOF | June 2020 | January 2024 | Allow | 43 | 2 | 1 | Yes | No |
| 16955391 | BIOMARKERS OF METHOTREXATE-INDUCED IMMUNE TOLERANCE | June 2020 | September 2024 | Allow | 51 | 1 | 2 | Yes | No |
| 16772262 | BCMA SPECIFIC VCAR COMPOSITIONS AND METHODS FOR USE | June 2020 | May 2024 | Allow | 47 | 2 | 1 | Yes | No |
| 16888989 | TARGETING B CELL ACTIVATING FACTOR RECEPTOR (BAFF-R) USING LIGAND-BASED CHIMERIC ANTIGEN RECEPTOR (CAR)-T CELLS | June 2020 | November 2023 | Allow | 41 | 2 | 1 | Yes | No |
| 16887460 | METHODS OF USING A BISPECIFIC ANTIGEN-BINDING CONSTRUCT TARGETING HER2 IN COMBINATION WITH CDK4/6 INHIBITORS FOR THE TREATMENT OF BREAST CANCER | May 2020 | May 2024 | Allow | 48 | 2 | 1 | Yes | No |
| 16646240 | Pharmaceutical Composition Comprising Antibody Binding Specifically to Lysyl-Trna Synthetase N-Terminus as Effective Ingredient for Preventing or Treating Immune Cell Migration-Related Disease | May 2020 | December 2023 | Allow | 45 | 2 | 1 | Yes | No |
| 16763134 | ANTI-C1S ANTIBODIES AND METHODS OF USE | May 2020 | April 2024 | Allow | 47 | 3 | 1 | Yes | No |
| 16648967 | ANTI-HLA-A2 ANTIBODIES AND METHODS OF USING THE SAME | March 2020 | March 2024 | Allow | 48 | 2 | 1 | No | No |
| 16645597 | COMPOSITIONS AND METHODS FOR REGULATION OF IMMUNE CELL ACTIVATION AND PROLIFERATION | March 2020 | January 2025 | Abandon | 58 | 4 | 1 | No | No |
| 16645428 | STREP-TAG SPECIFIC BINDING PROTEINS AND USES THEREOF | March 2020 | September 2024 | Abandon | 54 | 4 | 1 | No | No |
| 16808058 | Methods for Treating Patients with Hyperlipidemia by Administering a PCSK9 Inhibitor in Combination with an ANGPTL3 Inhibitor | March 2020 | October 2023 | Allow | 44 | 2 | 1 | No | No |
| 16784970 | ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE beta (HPTPbeta) AND USES THEREOF | February 2020 | June 2023 | Allow | 41 | 2 | 1 | Yes | No |
| 16632265 | METHODS OF QUALITATIVELY AND/OR QUANTITATIVELY ANALYZING PROPERTIES OF ACTIVATABLE ANTIBODIES AND USES THEREOF | January 2020 | June 2025 | Allow | 60 | 2 | 1 | No | Yes |
| 16609053 | METHOD FOR PREDICTING AND EVALUATING THERAPEUTIC EFFECT IN DISEASES RELATED TO IL-6 AND NEUTROPHILS | October 2019 | March 2023 | Allow | 41 | 3 | 1 | Yes | No |
| 16663791 | COMPOUND HAVING AFFINITY SUBSTANCE TO SOLUBLE PROTEIN, CLEAVABLE PORTION AND REACTIVE GROUP, OR SALT THEREOF | October 2019 | April 2024 | Allow | 53 | 2 | 0 | Yes | No |
| 16661669 | Binding Agents | October 2019 | November 2023 | Allow | 49 | 3 | 1 | Yes | No |
| 16500162 | ANTI-MASP-1 ANTIBODIES AND METHODS OF USE | October 2019 | July 2023 | Allow | 46 | 2 | 1 | No | No |
| 16484504 | CAR T-CELLS COMPRISING INACTIVATED CBL AND CBL-B GENES | August 2019 | September 2024 | Allow | 60 | 3 | 1 | Yes | No |
| 16480367 | ANTIGEN BINDING MOLECULES THAT BIND LIGHT | July 2019 | June 2023 | Allow | 47 | 2 | 1 | Yes | No |
| 16475876 | Biomarkers For Detecting Human Glycogen Phosphorylase Isoenzyme BB | July 2019 | September 2024 | Abandon | 60 | 2 | 1 | Yes | No |
| 16097021 | COMPOSITIONS AND METHODS FOR TREATING CANCER | October 2018 | February 2024 | Abandon | 60 | 3 | 1 | No | No |
| 15452669 | Treating Lymphomas | March 2017 | February 2025 | Allow | 60 | 13 | 0 | No | No |
| 15173186 | METHOD OF TREATING MULTIPLE SCLEROSIS USING ANTI-CD20 ANTIBODIES | June 2016 | February 2019 | Allow | 32 | 1 | 2 | Yes | No |
| 15027757 | METHODS OF IDENTIFYING SUBJECTS RESPONSIVE TO TREATMENT FOR TYPE 1 DIABETES AND COMPOSITIONS FOR TREATING THE SAME | April 2016 | August 2024 | Allow | 60 | 9 | 2 | Yes | Yes |
| 14979092 | ANTI-PCSK9 ANTIBODIES AND USE THEREOF | December 2015 | November 2018 | Allow | 35 | 1 | 1 | No | No |
| 14844475 | Methods for Treating Congestive Heart Failure | September 2015 | October 2018 | Allow | 38 | 2 | 1 | Yes | No |
| 14603231 | METHOD FOR TREATING MUSCLE WASTING SYNDROME USING ANTAGONIST ANTIBODIES AGAINST GDF-8 | January 2015 | November 2017 | Allow | 34 | 0 | 1 | Yes | No |
| 14571433 | NUCLEIC ACID ENCODING ANTIBODIES BINDING TO THE EXTRACELLULAR DOMAIN OF THE RECEPTOR TYROSINE KINASE ALK | December 2014 | August 2016 | Allow | 20 | 0 | 1 | No | No |
| 14562546 | NUCLEIC ACIDS ENCODING AN ANTIGEN BINDING PROTEINS TO PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 (PCSK9) | December 2014 | June 2015 | Allow | 6 | 5 | 1 | Yes | Yes |
| 14123533 | ANTI-C-MET ANTIBODY HAVING HGF ACTIVITY AND USE THEREOF | March 2014 | December 2016 | Allow | 36 | 0 | 1 | Yes | No |
| 14189288 | ANTIBODIES AGAINST FATTY ACID SYNTHASE | February 2014 | January 2016 | Allow | 23 | 0 | 0 | Yes | No |
| 14235970 | ANTIBODIES BINDING TO PHOSPHORYLCHOLINE (PC) AND/OR PC CONJUGATES | January 2014 | August 2017 | Allow | 43 | 2 | 1 | Yes | No |
| 14155903 | PHOSPHORYLCHOLINE CONJUGATES AND CORRESPONDING ANTIBODIES | January 2014 | October 2018 | Allow | 57 | 3 | 1 | Yes | No |
| 13883444 | MMP8 INACTIVATING ANTIGEN BINDING PROTEINS | October 2013 | July 2017 | Allow | 50 | 2 | 1 | Yes | No |
| 13940579 | VACCINE IMMUNOTHERAPY FOR TREATING HEPATOCELLULAR CANCER IN IMMUNE SUPPRESSED PATIENTS | July 2013 | February 2014 | Allow | 7 | 0 | 1 | Yes | No |
| 13910834 | METHOD FOR TREATING SARCOPENIA USING ANTAGONIST ANTIBODIES AGAINST GDF-8 | June 2013 | September 2014 | Allow | 16 | 0 | 0 | No | No |
| 13886180 | FORMULATIONS COMPRISING PCSK9 SPECIFIC MONOCLONAL ANTIBODIES | May 2013 | September 2019 | Allow | 60 | 4 | 1 | Yes | No |
| 13655984 | ANTIGEN BINDING PROTEINS TO PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 (PCSK9) | October 2012 | December 2023 | Abandon | 60 | 8 | 1 | Yes | Yes |
| 13605341 | METHODS OF DETECTING OXIDIZED CALCIUM/CALMODULIN DEPENDENT PROTEIN KINASE II | September 2012 | May 2015 | Allow | 32 | 0 | 0 | Yes | No |
| 13589652 | HEPATOCYTE GROWTH FACTOR (HGF) BINDING PROTEINS | August 2012 | June 2013 | Allow | 10 | 0 | 0 | No | No |
| 13576621 | METHODS FOR TREATMENT OF CUSHING'S DISEASE AND HYPERCORTISOLISM USING GEFITINIB | August 2012 | March 2016 | Allow | 43 | 2 | 1 | No | No |
| 13562863 | USE OF GOAT SERUM FOR VETERINARY TREATMENT | July 2012 | August 2013 | Allow | 13 | 1 | 1 | No | No |
| 13547548 | POLYNUCLEOTIDE ENCODING ANTI-CD14 ANTIBODY FUSION PROTEIN | July 2012 | May 2013 | Allow | 10 | 0 | 1 | Yes | No |
| 13524465 | COMPLEMENT INHIBITORS AND USES THEREOF | June 2012 | August 2014 | Allow | 26 | 2 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner WEN, SHARON X.
With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 21.1% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner WEN, SHARON X works in Art Unit 1641 and has examined 170 patent applications in our dataset. With an allowance rate of 83.5%, this examiner has an above-average tendency to allow applications. Applications typically reach final disposition in approximately 34 months.
Examiner WEN, SHARON X's allowance rate of 83.5% places them in the 52% percentile among all USPTO examiners. This examiner has an above-average tendency to allow applications.
On average, applications examined by WEN, SHARON X receive 1.80 office actions before reaching final disposition. This places the examiner in the 54% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by WEN, SHARON X is 34 months. This places the examiner in the 22% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +18.7% benefit to allowance rate for applications examined by WEN, SHARON X. This interview benefit is in the 65% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 30.6% of applications are subsequently allowed. This success rate is in the 53% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.
This examiner enters after-final amendments leading to allowance in 47.1% of cases where such amendments are filed. This entry rate is in the 66% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 120.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 80% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.
This examiner withdraws rejections or reopens prosecution in 83.3% of appeals filed. This is in the 73% percentile among all examiners. Of these withdrawals, 90.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 61.0% are granted (fully or in part). This grant rate is in the 78% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 18.2% of allowed cases (in the 99% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 2% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.